Market open
iCAD/$ICAD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About iCAD
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
Ticker
$ICAD
Sector
Trading on
Industry
Health Care Technology
Headquarters
Employees
68
Website
iCAD Metrics
BasicAdvanced
$98M
-
-$0.10
1.48
-
Price and volume
Market cap
$98M
Beta
1.48
52-week high
$3.75
52-week low
$1.18
Average daily volume
440K
Financial strength
Current ratio
4.019
Quick ratio
3.727
Long term debt to equity
0.65
Total debt to equity
1.413
Interest coverage (TTM)
-437.14%
Management effectiveness
Return on assets (TTM)
-8.95%
Return on equity (TTM)
-17.56%
Valuation
Price to revenue (TTM)
5.147
Price to book
3.32
Price to tangible book (TTM)
4.67
Price to free cash flow (TTM)
-19.827
Growth
Revenue change (TTM)
10.03%
Earnings per share change (TTM)
-73.95%
3-year revenue growth (CAGR)
-19.48%
3-year earnings per share growth (CAGR)
-34.51%
What the Analysts think about iCAD
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for iCAD stock.
iCAD Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
iCAD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
iCAD News
AllArticlesVideos
iCAD Pre-Announces Estimated Q4 2024 Revenue
GlobeNewsWire·3 days ago
Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions
Newsfile Corp·2 weeks ago
SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for iCAD stock?
iCAD (ICAD) has a market cap of $98M as of January 30, 2025.
What is the P/E ratio for iCAD stock?
The price to earnings (P/E) ratio for iCAD (ICAD) stock is 0 as of January 30, 2025.
Does iCAD stock pay dividends?
No, iCAD (ICAD) stock does not pay dividends to its shareholders as of January 30, 2025.
When is the next iCAD dividend payment date?
iCAD (ICAD) stock does not pay dividends to its shareholders.
What is the beta indicator for iCAD?
iCAD (ICAD) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.